PHILADELPHIA, Aug. 20, 2013 (GLOBE NEWSWIRE) -- Hemispherx Biopharma (NYSE MKT:HEB) announced that one of its advanced stage biological products, Alferon N(R), will be featured as part of a new experimental program designed to potentially limit the spread and lethality of the pandemic influenza virus designated H7N9. Professor Richt, Director of the U.S. Department of Homeland Security Center of Excellence for Emerging and Zoonotic Animal Diseases (CEEZAD), will present his program to potentially reduce the spread of influenza from animals to man. Professor Richt, who is a scientific adviser to Hemispherx Biopharma, will discuss new experiments on the possible inhibition of Tamiflu-resistant H7N9 virus by Alferon N(R) and the potential use of Alferon(R) LDO (a low dose oral formulation of Alferon N(R)) in animals that are considered "mixing vessels" in that they support potential influenza reassortment and virulence. The conference will take place at the Holiday Inn, Orlando International Airport, on August 21-23.
This is great news!
HEB MIGHT be able use one of their products on farm animals... sound exciting and worthy of a PR from HEB. Maybe they will change the name to Hemispherx Zoopharma. The leader in animal drugs that fail to work on humans. Maybe they can use Ampligen on farm animals who have CFS since it has no other use.